Stay updated with breaking news from Edwarde Walsh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK - Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved ABRYSVO , the company's bivalent RSV prefusion F vaccine, for the prevention of lower respiratory... | June 1, 2023
The FDA has approved Abrysvo for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
The approval for Abrysvo represents the second RSV vaccine approved for adults aged 60 years and older in the last month.
FDA’s decision is based on the data from the pivotal Phase 3 clinical trial in approximately 37,000 participants Each year in the U.S., it is estimated that between 60,000 and 160,000 older... | June 10, 2023
Findings seen in phase 3 trial of adults aged 60 years and older receiving a single intramuscular injection of RSVpreF vaccine.